Fasting reduces tear production

Article

Fasting significantly reduces the amount of tears produced by the eye and increases the osmolarity of the tears, according to new research.

Fasting significantly reduces the amount of tears produced by the eye and increases the osmolarity of the tears, according to new research published in Eye & Contact Lens: Science & Clinical Practice. Fasting does not deteriorate the parameters of corneal topography or ocular aberrations in people who are healthy, however.

The study authors conducted a prospective controlled study of 29 eyes in 29 healthy men (mean age, 27.8 ± 5.9 years; range, 20 to 47 years). All of the men underwent corneal topography via a placido disc corneal topography and aberrometry device (OPD-Scan II, Nidek) before their ophthalmic examinations. Researchers used an osmometer (OcuSense, Tear Lab) to measure tear osmolarity. They also evaluated ocular surface disease index (OSDI) scores, tear break-up time (BUT), Schirmer I test and lissamine green staining.

The investigators took measurements between 4 pm and 5 pm before and during Ramadan and compared them using paired sample t test, considering a P value of less than 0.05 as statistically significant.

The researchers found:

  • The mean tear osmolarity values were 285.6 ± 8.2 mOsm/L in nonfasting periods and 293.3 ± 16.0 mOsm/L in fasting periods.
  • The mean Schirmer I values were 14.8 ± 6.0 mm in nonfasting periods and 10.6 ± 5.3 mm in fasting periods.
  • Tear osmolarity, OSDI and Oxford grading scores significantly increased during the fasting period compared with the nonfasting period.
  • Schirmer I values and IOP decreased during the fasting period compared with the nonfasting period.
  • No significant differences occurred in tear BUT, keratometry values and corneal aberration measurements in nonfasting periods compared with fasting periods.

To read an abstract of the study, click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.